Studies of the Effects of Perfluorocarbon Emulsions on Platelet Number and Function in Models of Critical Battlefield Injury
Abstract
Perfluorocarbon emulsions (PFCs) may use to treat traumatic injuries by enhanced delivery of oxygen. A concerned side effect of PFC may cause thrombocytopenia (TCYP). FDA requests investigation of the phenomenon to exclude Platelet (Plt) inflammatory/embolic safety risks prior to clinical trial. The results (phase I, n=32, 4 groups) showed that PFC given to the normal sheep did not significantly change the Plt number and activation compared with the control groups. In the Phase II and III studies, PFCs as an adjuvant resuscitation fluid were added to the hemorrhagic shock (n=39, 4 groups) or polytrauma (blast traumatic injury and hemorrhage, n=20, 2 groups) sheep after initial resuscitation with hespan until the mean arterial pressure reached to 55 mmHg. The results showed that the Plt number were reduced after immediately resuscitation in all injured groups. However, PFCs did not exaggerate the change of Plt number and activation comparing with non-PFC controls over the 7 survival days. Plt mean volume, Plt aggregation, Thrombin potential by CAT, Plt CD-62, fibrinogen level also showed no significant change compared with control groups. Quantitative Plt morphological activation (observation with scanning electron microscopy) was correspond with the results of functional assays. There are no significant percentage changes in circulating neutrophils and monocytes after PFC infusion in normal or injured sheep models. Therefore, the intravenous infusion of PFCs in healthy and hemorrhagic sheep would not cause massive or severe coagulopathy.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2016
- Accession Number
- AD1024718
Entities
People
- Bruce D Spiess
- Donald Brophy
- Erika J. Martin
- Jiepei Zhu
- John T. Parsons
- Penny S. Reynolds
Organizations
- Virginia Commonwealth University